Home › Breast Cancer › Minnesota
Breast Cancer clinical trials in Minnesota
64 studies for Breast Cancer are looking for participants at sites in Minnesota.
Cities in Minnesota
- Rochester39 studies
- Minneapolis23 studies
- Saint Paul12 studies
- Plymouth8 studies
- Duluth7 studies
- Brooklyn Park6 studies
- Bloomington5 studies
- Saint Cloud4 studies
- Mankato3 studies
Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
- Mayo Clinic - Rochester, Rochester
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 13, 2026 · NCT05696626S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity
- Mercy Hospital, Coon Rapids
- Minnesota Oncology Hematology PA-Maplewood, Maplewood
- Abbott-Northwestern Hospital, Minneapolis
- and 6 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 12, 2026 · NCT03418961Trial of 225Ac-DOTATATE (RYZ101) in Subjects With ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs.
- Research Facility, Rochester
RecruitingPhase 1/2
All ages · All sexes · Updated Nov 12, 2026 · NCT06590857ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer
- Mayo Clinic Cancer Center, Rochester
- HealthPartners Frauenshuh Cancer Center, Saint Louis Park
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Nov 9, 2026 · NCT07007559A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer
- Metro-Minnesota Community Oncology Research Consortium, Saint Paul
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Nov 6, 2026 · NCT03424005The Vanguard Study: Testing a New Way to Screen for Cancer
- Minneapolis VA Medical Center, Minneapolis
RecruitingHealthy volunteers welcome
Ages 45 to 75 · All sexes · Updated Nov 6, 2026 · NCT06995898Collecting Patient-Reported Experiences With Radiation Dermatitis in Breast Cancer Patients Undergoing Radiotherapy
- Mayo Clinic in Rochester, Rochester
RecruitingObservational study
Ages 18 and older · All sexes · Updated Nov 5, 2026 · NCT06953245Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer
- Mayo Clinic, Rochester
Recruiting
Ages 18 and older · All sexes · Updated Nov 5, 2026 · NCT07214532Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration
- Mayo Clinic, Rochester
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Nov 5, 2026 · NCT05315700Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
- Minnesota Oncology Hematology, P.A., Minneapolis
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 5, 2026 · NCT06982521A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
- Allina Health Cancer Institute - Abbott Northwestern Hospital, Minneapolis
- Mayo Clinic in Rochester, Minnesota, Rochester
- Metro-Minnesota Community Clinical Oncology, Saint Louis Park
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 4, 2026 · NCT07174336A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
- University of Minnesota Medical Center, Minneapolis
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 4, 2026 · NCT06790693E-Mindfulness Approaches for Living After Breast Cancer
- Essentia Health Saint Joseph's Medical Center, Brainerd
- Essentia Health Cancer Center, Duluth
- Mayo Clinic Health Systems-Mankato, Mankato
- and 1 more
RecruitingPhase 3
Ages 18 to 50 · All sexes · Updated Nov 4, 2026 · NCT06748222A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer
- Mayo Clinic in Rochester, Minnesota, Rochester
RecruitingPhase 2
Ages 18 and older · Women · Updated Nov 4, 2026 · NCT07287098Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Riverwood Healthcare Center, Aitkin
- Mayo Clinic Health System in Albert Lea, Albert Lea
- Essentia Health - Baxter Clinic, Baxter
- and 49 more
RecruitingObservational studyHealthy volunteers welcome
Ages 40 to 75 · All sexes · Updated Nov 4, 2026 · NCT05334069Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
- USOR Minnesota Oncology Hematology, Maplewood
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Nov 4, 2026 · NCT05579366Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
- Mayo Clinic Health System in Albert Lea, Albert Lea
- Essentia Health Saint Joseph's Medical Center, Brainerd
- Minnesota Oncology - Burnsville, Burnsville
- and 33 more
RecruitingObservational study
Ages 18 and older · All sexes · Updated Nov 4, 2026 · NCT06418204A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
- Mayo Clinic - Rochester, Rochester
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 4, 2026 · NCT07213791Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
- Riverwood Healthcare Center, Aitkin
- Essentia Health - Baxter Clinic, Baxter
- Sanford Joe Lueken Cancer Center, Bemidji
- and 48 more
RecruitingPhase 3
Ages 18 to 60 · Women · Updated Nov 4, 2026 · NCT05879926A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus Ribociclib Plus Fulvestrant in Participants With Advanced Breast Cancer
- Avera Cancer Institute - Marshall, Marshall
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Nov 3, 2026 · NCT07405801ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
- Healthpartners Regions Specialty Clinics, Saint Louis Park
- Healthpartners Regions Specialty Clinics, Saint Paul
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Oct 30, 2026 · NCT07173751A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
- Mayo Rochester, Rochester
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 28, 2026 · NCT07109726Avera Cancer Sequencing and Analytics Protocol (ASAP)
- Avera Cancer Institute - Marshall, Marshall
RecruitingObservational study
Ages 18 and older · All sexes · Updated Oct 28, 2026 · NCT05142033EXActDNA-003 / NSABP B-64: Study of Molecular Residual Disease Detection in Breast Cancer (MRD)
- Metro Minnesota Community Oncology Consortium (MMCORC), Saint Louis Park
RecruitingObservational study
Ages 18 and older · All sexes · Updated Oct 27, 2026 · NCT06401421A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
- Health Partners Frauenshuh Cancer Center, Saint Louis Park
- Health Partners Cancer Center at Regions Hospital, Saint Paul
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Oct 26, 2026 · NCT06172478Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors
- Minnesota Oncology-Sarah Cannon Research Institute, Maple Grove
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 22, 2026 · NCT07287917A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
- Minnesota Oncology Hematology, P.A., Burnsville
- Minnesota Oncology Hematology, P.A., Coon Rapids
- Minnesota Oncology Hematology, P.A., Edina
- and 5 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Oct 19, 2026 · NCT07062965Zunsemetinib in Combination With Capecitabine in Patients With Hormone Receptor-Positive and HER2-Negative Metastatic Breast Cancer With Bone Metastasis
- Mayo Clinic, Rochester
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 13, 2026 · NCT06374459Phase 1 Study of CLR 125 in Triple Negative Breast Cancer
- Mayo Clinic Rochester, Rochester
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 8, 2026 · NCT07311993Molecular Breast Imaging Guidance for Breast Biopsy for Patients With Breast Abnormalities
- Mayo Clinic in Rochester, Rochester
Recruiting
Ages 18 and older · Women · Updated Oct 5, 2026 · NCT06058650A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer
- University of Minnesota, Masonic Cancer Center, Minneapolis
- Mayo Clinic, Rochester
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Oct 1, 2026 · NCT06369285Low Dose Aspirin for the Prevention of Postpartum Related Breast Cancer
- Mayo Clinic in Rochester, Rochester
RecruitingPhase 2Healthy volunteers welcome
Ages 18 to 45 · Women · Updated Oct 1, 2026 · NCT05557877PRE-ISPY Phase I/II Oncology Platform Program
- University of Minnesota Masonic Cancer Center, Minneapolis
- Mayo Clinic Comprehensive Cancer Center, Rochester
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 30, 2026 · NCT05868226Multicenter Trial for Eliminating Breast Cancer Surgery or Radiotherapy in Exceptional Responders to Neoadjuvant Systemic Therapy
- Mayo Clinic, Rochester
Recruiting
Ages 30 and older · Women · Updated Sep 25, 2026 · NCT02945579A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
- Research Site, Saint Paul
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT06103864Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
- Clinical Trial Site, Minneapolis
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 23, 2026 · NCT07085767Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies
- Mayo Clinic, Rochester
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 18, 2026 · NCT07340541FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors
- University of Minnesota Masonic Cancer Center, Minneapolis
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 2, 2026 · NCT07216105Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.
- Mayo Clinic-Comprehensive Cancer Center-Breast Clinic, Rochester
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 2, 2026 · NCT06072612Phase Ib Study of Axatilimab in Combination With Olaparib in BRCA1/2 and PALB2- Associated Metastatic HER2-negative Breast Cancer
- Mayo Clinic, Rochester
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 2, 2026 · NCT06488378From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.